Results 141 to 150 of about 19,748 (182)
Some of the next articles are maybe not open access.
Amyloidosis and Light Chain Plasmocytoma
Tumori Journal, 1976Nine cases of light chain plasmocytomas, 6 type λ and 3 type k, have been studied in reference to amyloid presence and localisation. Bone marrow plasmocytosis, light chains in serum and/or in the urine, and osteolytic lesions were demonstrated in all the patients.
G, Tosato, E, Fagiolo
openaire +2 more sources
Advances in the treatment of light chain amyloidosis
Current Opinion in Oncology, 2022Purpose of review After many years, the management of systemic light chain (AL) amyloidosis is entering the era of evidence-based medicine, with three recently published randomized clinical trials, a regimen (daratumumab, cyclophosphamide, bortezomib, and dexamethasone, daratumumab-CyBorD) labeled for upfront therapy, more ...
Palladini, Giovanni, Milani, Paolo
openaire +3 more sources
Macroglossia in Light-Chain Amyloidosis
New England Journal of Medicine, 2018Macroglossia in Light-Chain Amyloidosis A 78-year-old man presented with enlargement and stiffening of the tongue. Biopsy confirmed that this finding of macroglossia was due to light-chain amyloidosis.
João Melo Alves, Natália Marto
openaire +2 more sources
Coagulation Abnormalities in Light Chain Amyloidosis
Mayo Clinic Proceedings, 2021To assess the prevalence of coagulation abnormalities in patients with systemic light chain (AL) amyloidosis and their association with disease-related characteristics, disease progression, and survival.This is a retrospective study of patients with AL amyloidosis seen at Mayo Clinic, Rochester, Minnesota, from January 1, 2006, to December 31, 2015. We
Nadine Abdallah +16 more
openaire +2 more sources
Immunoglobulin light chain amyloidosis
Expert Review of Hematology, 2013Primary light chain amyloidosis is the most common form of systemic amyloidosis and is caused by misfolded light chains that cause proteotoxicity and rapid decline of vital organ function. Early diagnosis is essential in order to deliver effective therapy and prevent irreversible organ damage.
MERLINI, GIAMPAOLO +4 more
openaire +3 more sources
Innere Medizin (Heidelberg, Germany), 2023
Light chain amyloidosis (AL) is a rare protein deposition disease. It is caused by a clonal plasma cell or B‑cell disease in the bone marrow. With the exception of the central nervous system, all organs can be affected by amyloid deposits. Cardiac involvement is the most frequent organ manifestation that leads to significantly increased mortality when ...
Ute, Hegenbart +2 more
openaire +1 more source
Light chain amyloidosis (AL) is a rare protein deposition disease. It is caused by a clonal plasma cell or B‑cell disease in the bone marrow. With the exception of the central nervous system, all organs can be affected by amyloid deposits. Cardiac involvement is the most frequent organ manifestation that leads to significantly increased mortality when ...
Ute, Hegenbart +2 more
openaire +1 more source
Treatment of immunoglobulin light chain amyloidosis
Current Hematologic Malignancy Reports, 2009No therapy is uniformly effective in the management of immunoglobulin light chain amyloidosis (AL amyloidosis). Despite the common generalization, therapy is highly effective. Options available to patients with AL amyloidosis include high-dose therapy, but this is applicable to only about one fourth of patients.
Morie A, Gertz, Steven R, Zeldenrust
openaire +2 more sources
Immunoglobulin Light Chain Systemic Amyloidosis
2016Immunoglobulin light chain amyloidosis (AL) is a rare, complex disease caused by misfolded free light chains produced by a usually small, indolent plasma cell clone. Effective treatments exist that can alter the natural history, provided that they are started before irreversible organ damage has occurred.
Angela, Dispenzieri, Giampaolo, Merlini
openaire +2 more sources
2016
Light-chain (AL) amyloidosis is the most common cause of acquired systemic amyloidosis. It is a highly heterogeneous disease with a wide spectrum of clinical presentation. Prognosis of AL amyloidosis depends on organ, particularly cardiac, involvement.
Amara S. Hussain, Anita D’Souza
openaire +1 more source
Light-chain (AL) amyloidosis is the most common cause of acquired systemic amyloidosis. It is a highly heterogeneous disease with a wide spectrum of clinical presentation. Prognosis of AL amyloidosis depends on organ, particularly cardiac, involvement.
Amara S. Hussain, Anita D’Souza
openaire +1 more source
Amyloid Formation in Light Chain Amyloidosis
Current Topics in Medicinal Chemistry, 2013Light chain amyloidosis is one of the unique examples within amyloid diseases where the amyloidogenic precursor is a protein that escapes the quality control machinery and is secreted from the cells to be circulated in the bloodstream. The immunoglobulin light chains are produced by an abnormally proliferative monoclonal population of plasma cells that
openaire +2 more sources